Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 2:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 3,445 matching trials from the live ClinicalTrials.gov search.
Conditions
Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Papillary Thyroid Cancer, Melanoma, Colorectal Adenocarcinoma
Interventions
CM-24 and Nivolumab - Dose Escalation, CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, Nivolumab and Nal-IRI/5-FU/LV - Expansion
Drug
Lead sponsor
Famewave Ltd.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 2 more
Conditions
Obesity
Interventions
ISIS-FGFR4RX, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Postmenopausal Women With Osteoporosis
Interventions
GP2411, EU-Prolia (EU-authorized Prolia®)
Biological
Lead sponsor
Sandoz
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Peoria, Arizona • Miami, Florida • Wichita, Kansas + 3 more
Completed Phase 1 Interventional Accepts healthy volunteers

Methylphenidate-Duloxetine Combinations for Cocaine Dependence

NCT02700711
Conditions
Cocaine Use Disorder
Interventions
Methylphenidate, Placebo, Duloxetine
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Chronic Graft-versus-host Disease (cGVHD)
Interventions
AMG 592, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Aventura, Florida
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effect of Ethanol and Genetic Polymorphisms on Bupropion Metabolism

NCT00330434
Conditions
Alcohol Drinking, Depression, Smoking Cessation, Attention Deficit Disorder
Interventions
Trial Withdrawn 1, Trial Withdrawn 2
Other
Lead sponsor
Tufts University
Other
Eligibility
21 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Metastatic Solid Tumors, Locally Advanced Solid Tumors
Interventions
OBI-888, Globo H IHC Assay
Drug · Device
Lead sponsor
OBI Pharma, Inc
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 3 more
Conditions
Healthy
Interventions
bococizumab PFS:Pfizer, bococizumab PFS: BIP, bococizumab PFP
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
470 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
5
States / cities
Hollywood, Florida • South Miami, Florida • Saint Paul, Minnesota + 1 more
Conditions
Systemic Lupus Erythematosus
Interventions
DS-7011a, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Long Beach, California • San Antonio, Texas
Conditions
Hepatitis C
Interventions
Single Ascending Dose Cohorts GS-9620, Multiple Ascending Dose Cohorts GS-9620
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Little Rock, Arkansas • DeLand, Florida • Orlando, Florida + 7 more
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

n-Acetylcysteine and Cocaine

NCT02141620
Conditions
Cocaine Abuse, Cocaine Dependence
Interventions
Cocaine, n-Acetylcysteine, Placebo
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Neoplasms, Solid Tumor, Adult, Non-Hodgkin Lymphoma, Myelodysplastic Syndromes
Interventions
JNJ-64619178
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Sarasota, Florida • Boston, Massachusetts • Columbus, Ohio + 1 more
Conditions
Fabry Disease
Interventions
GZ/SAR402671
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Atlanta, Georgia • Cincinnati, Ohio • Fairfax, Virginia
Conditions
Psychiatric or Mood Diseases or Conditions
Interventions
Pharmacogenetic test
Diagnostic Test
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4178256 in Healthy Participants

NCT07698210
Conditions
Healthy Volunteers
Interventions
LY4178256, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Los Alamitos, California • Salt Lake City, Utah
Conditions
Fabry Disease
Interventions
migalastat HCl
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Decatur, Georgia • New York, New York • Dallas, Texas
Conditions
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Interventions
Satralizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, raltitrexed
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers

Oral CXA-10 Study in Healthy Volunteers

NCT02313064
Conditions
Chronic Kidney Injury
Interventions
CXA-10, CXA-10 placebo
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Kalamazoo, Michigan
Conditions
Non Alcoholic Steatohepatitis
Interventions
Elafibranor 80mg, Elafibranor 120mg
Drug
Lead sponsor
Genfit
Industry
Eligibility
8 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
San Diego, California • New York, New York
Conditions
Urinary Bladder, Overactive
Interventions
warfarin, Warfarin plus Fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GSP304 (tiotropium bromide) Inhalation Solution, GSP304 Placebo Inhalation Solution, Spiriva® Respimat® inhalation spray
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
40 Years to 85 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
25
States / cities
Andalusia, Alabama • Phoenix, Arizona • Tempe, Arizona + 18 more
Conditions
Healthy
Interventions
0.1 mg PF-04995274, 1 mg PF-04995274, 10 mg PF-04995274, 15 mg PF-04995274, 1.0 mg PF-04995274
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Overland Park, Kansas
Conditions
Magnesium Sulfate Pharmacokinetics and Pharmacodynamics
Interventions
Magnesium sulfate infusion
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Stanford, California